Mind + Muscle

technical minds + legal muscle


dig deep

Big Pharma and Section 337: The Next Frontier

  • 05.10.11
  • Daniel E. Yonan, Keeto Sabharwal, Mark Fox Evens, and Jeremiah Frueauf
  • World Intellectual Property Review

With its recent vote to institute Investigation No. 337-TA-766, entitled Certain Gemcitabine and Products Containing Same, the United States International Trade Commission may have opened a new frontier for enforcing non-Orange Book listed patents. Investigations under Section 337 have traditionally been used by patent holders in the electrical and mechanical industries. However, as a result of the Commission’s decision, innovators may now begin using the Section 337 process to frustrate post-Orange Book patent certainty by adding additional barriers, significant risk and expense to generic drug entry into the US. This investigation represents a test case for an innovator to leverage the patents it has in its portfolio against generics that have approval to market a generic drug product, even after the Orange Book listed patents have either expired or been declared invalid.

For a more detailed look at this new avenue, see the attached PDF above.

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.